Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Coya Therapeutics, Inc.NASDAQ: COYA
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$50.72M, compared with -$35.53M a year earlier.
Context
- Net debt amounted to 95.2% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Net debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -42.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (46.82M) USD
- Year-over-year change
- -22.1%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (46.82M) | -22.1% |
| FY2024 | 2024-12-31 | (38.34M) | -17.5% |
| FY2023 | 2023-12-31 | (32.63M) | -564.0% |
| FY2022 | 2022-12-31 | 7.03M | +262.0% |
| FY2021 | 2021-12-31 | (4.34M) | — |
Net Debt vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's Mar 2026 net debt of -$50.72M is the 7th highest of the 11 companies compared; the peer median is -$32.4M.
- Its year-over-year change of -42.8% is the 8th highest of 11, against a peer median of +58.6%.
- Net debt amounts to 95.2% of total assets for COYA, versus a peer median of 34.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $16.11M | +45.0% | +6.9% | 74.4% | |
| Mar 2026 | $6.72M | +2809.5% | -5.6% | 2.7% | |
| Mar 2026 | $6.59M | +120.8% | — | 3.3% | |
| Mar 2026 | -$12.44M | +83.2% | — | 4.6% | |
| Mar 2026 | -$30.01M | +72.2% | — | 13.8% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | -$34.79M | +84.7% | — | 27.3% |
| Mar 2026 | -$50.72M | -42.8% | — | 95.2% | |
| Mar 2026 | -$54.25M | +39.2% | — | 92.2% | |
| Mar 2026 | -$78.21M | -426.3% | — | 81.6% | |
| Mar 2026 | -$87.53M | -51.7% | — | 85.7% | |
| Mar 2026 | -$92.61M | -1280.9% | — | 41.0% | |
| Peer median (excluding COYA) | -$32.4M | +58.6% | +0.6% | 34.2% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 5.93M | 32.63M | 38.34M | 46.82M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 7.5M | 730.58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 4.58M | 7.18M | 41.2M | 44.31M | 49.94M |
| Property, Plant & Equipment (Net) | 120.67K | 93.31K | 65.95K | 38.59K | 11.23K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87.18K | 1.12M | 0 | 0 | 0 |
| Total Non-current Assets | 207.85K | 1.21M | 65.95K | 38.59K | 11.23K |
| Total Assets | 4.79M | 8.4M | 41.26M | 44.35M | 49.95M |
| Account Payables | 857.57K | 1.82M | 1.16M | 1.59M | 1.06M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 723.85K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 923.11K | 848.29K | 1.2M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.15M | 3.82M | 5.05M | 3.82M | 5.87M |
| Long-term Debt | 0 | 12.97M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 574.69K | 945.45K | 1.05M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 12.97M | 574.69K | 945.45K | 1.05M |
| Total Liabilities | 1.15M | 16.79M | 5.63M | 4.77M | 6.92M |
| Common Stock | 259 | 259 | 1.44K | 1.67K | 2.09K |
| Retained Earnings | (5.62M) | (17.87M) | (25.86M) | (40.74M) | (61.96M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (11.25K) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.64M | (8.39M) | 35.64M | 39.58M | 43.03M |
| Total Debt | 0 | 12.97M | 0 | 0 | 0 |
| Net Debt | (4.34M) | 7.03M | (32.63M) | (38.34M) | (46.82M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.